NCT07444164

Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

Comparative Study to Evaluate the Relative Bioavailability Between a Fixed-dose Combination Product of 90 mg Ticagrelor/100 mg Acetylsalicylic Acid vs Administration of the Reference Monotherapies in Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Laboratorios Silanes S.A. de C.V. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) administered concomitantly versus the fixed-dose combination of Ticagrelor 90 mg / Acetylsalicylic Acid 100 mg manufactured by Laboratorios Silanes S.A. de C.V.

Detailed description

Prospective, longitudinal, open-label, single-dose per period, two treatments two periods, crossover, balanced, randomized study with a 7-day washout period in 20 plus 4 (24) healthy research subjects of both genders, under fasting conditions. In order to establish characterization of the pharmacokinetic parameters Cmax, Tmax, T1/2, Ke, (AUC 0-t) and the (AUC 0-\~) when administered as a single dose of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) as a reference formulation and the fixed-dose combination of Ticagrelor 90 mg/ Acetylsalicylic Acid 100 mg as the test formulation manufactured by Laboratorios Silanes S.A. de C.V.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.)	Formula: 90 mg/ 100 mg Pharmaceutical Form: Capsule Dosage: 1 capsule (90 mg/ 100mg) Administration way: oral
DRUG	A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)	A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral A3: Pharmaceutical Form: Tablet Formula: Each tablet contains 100 mg Dosage: 1 tablet of 100 mg Administration way: oral

Timeline

• Start date: 2025-01-13
• Primary completion: 2025-01-23
• Completion: 2025-02-05
• First posted: 2026-03-02
• Last updated: 2026-03-02

Locations

1 site across 1 country: Mexico